Rtw Investments Adds $33M in Aktis Oncology, Inc. ($AKTS)
RTW Investments took a fresh position in AKTS, buying 1.59 million shares.
Key Points
- RTW Investments acquired 1.59 million shares of AKTS, valued at about $33.48 million, as per its latest 13F filing.
- AKTS shares are trading around $21.03, with several institutional investors adjusting their positions.
- Insiders have been active, with significant buying and selling, while analysts maintain positive ratings.
RTW Investments has taken a new position in AKTS, acquiring 1,592,043 shares. This move, reported in their latest 13F filing with the SEC, marks a fresh investment valued at approximately $33.48 million. The filing reflects holdings as of the reporting period and may not represent RTW's current position.
What Changed in RTW Investments' AKTS Position
RTW Investments' new stake in AKTS consists of 1,592,043 shares, making it a significant entry without prior holdings. The value of this position stands at about $33.48 million, underscoring a notable addition to their portfolio.
Other Institutional Activity in AKTS
Several other funds have also adjusted their positions in AKTS. MPM BioImpact LLC added 4,835,872 shares, bringing its total to 4,835,872 shares valued at approximately $86.51 million. ECOR1 Capital, LLC similarly increased its holdings by 4,824,469 shares, ending with 4,824,469 shares worth about $86.31 million. Blue Owl Capital Holdings LP acquired 3,161,348 shares, valued at around $56.56 million. Wellington Management Group LLP added 2,317,044 shares, totaling 2,317,044 shares valued at $41.45 million. T. Rowe Price Investment Management, Inc. and BlackRock, Inc. also increased their stakes, holding 2,123,812 and 2,112,127 shares, respectively.
AKTS Stock Snapshot
Shares of AKTS are currently trading around $21.03. The stock has seen various institutional investors adjusting their positions, indicating active interest in the company. The current market dynamics and institutional movements could influence future trading and investment decisions.
Insider Buying and Selling at Aktis Oncology, Inc.
Insider activity at AKTS has been notable. On April 15, 2026, Glenn Gormley purchased 37,866 shares. Earlier in the year, on January 12, Todd Foley bought 4,002,533 shares and sold 10,227,273 shares. Ansbert Gadicke sold 5,000,000 shares, while MPM Bioventures 2018, L.P. sold 6,000,000 shares. Additionally, Todd Foley acquired 232,870 shares at $18 per share on January 12.
Analysts Set New Price Targets
Analyst activity around AKTS has been active. On June 2, 2026, HC Wainwright & Co. maintained a buy rating with a price target of $35. Earlier, on March 31, they maintained a buy rating with a target of $33. They initiated coverage on March 9 with a buy rating and a target of $30. Leerink Partners and JP Morgan both initiated coverage on February 3 with buy ratings and targets of $31 and $30, respectively.
About AKTS
AKTS operates in the technology sector, focusing on solutions for wireless devices. Their innovations aim to enhance communication technology, catering to a growing demand for efficient and reliable wireless solutions. The company continues to expand its offerings, driven by advancements in technology and market needs.
Bottom Line
RTW Investments' new stake in AKTS is a significant move in the tech sector. Investors closely watch 13F filings to gauge institutional sentiment, though these filings reflect past positions. AKTS's active insider trading and positive analyst ratings highlight ongoing interest and potential in the stock.
See Also
This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.